 Eduardo Davila
| Title | Professor |
|---|
| Institution | University of Colorado Denver - Anschutz Medical Campus |
|---|
| Department | SOM-MED |
|---|
| Phone | 303/724-0817 |
|---|
|
|
|
 Research R01CA271537 (DAVILA, EDUARDO V)May 3, 2023 - Apr 30, 2028 NIH
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity
Role: Principal Investigator |
| R25GM140243 (DAVILA, EDUARDO V)Feb 1, 2022 - Jan 31, 2027 NIH
Colorado Preparation in Interdisciplinary Knowledge to Excel PREP
Role: Principal Investigator |
| I01BX004935 (DAVILA, EDUARDO V)Apr 1, 2020 - Mar 31, 2025 NIH
Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity
Role: Principal Investigator |
| T32CA236734 (JIMENO, ANTONIO)Jul 8, 2019 - Jun 30, 2025 NIH
Cancer Immunotherapy and Experimental Therapeutics - T32
Role: Co-Principal Investigator |
| R01CA207913 (DAVILA, EDUARDO V)Apr 1, 2017 - Mar 31, 2022 NIH
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition
Role: Principal Investigator |
| R25GM113262 (CAREY, GREGORY B)Mar 1, 2016 - Feb 28, 2026 NIH
UMB Postbaccalaureate Research Education Program
Role: Co-Principal Investigator |
| I01BX002142 (DAVILA, EDUARDO)Jan 1, 2015 - Dec 31, 2019 NIH
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target
Role: Principal Investigator |
| R01CA166961 (RAPOPORT, AARON P)Sep 1, 2012 - Aug 31, 2017 NIH
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
Role: Co-Principal Investigator |
| R01CA140917 (DAVILA, EDUARDO)Jun 1, 2009 - May 31, 2015 NIH
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation
Role: Principal Investigator |
Bibliographic
-
Kent A, Crump LS, Davila E. Beyond a? T cells: NK, iNKT, and ?dT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML. Front Immunol. 2023; 14:1202950. PMID: 37654497.
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219. PMID: 36378549.
-
Guo J, Kent A, Davila E. Chimeric non-antigen receptors in T cell-based cancer therapy. J Immunother Cancer. 2021 08; 9(8). PMID: 34344725.
-
Kent A, Longino NV, Christians A, Davila E. Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy. Front Immunol. 2021; 12:658611. PMID: 34012443.
-
Mar?n-Jim?nez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021; 12:607282. PMID: 33854497.
-
Younis RH, Ghita I, Elnaggar M, Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon LJ, Papadimitriou JC, Webb TJ, Bentzen SM, Lubek JE. Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Front Immunol. 2021; 12:596646. PMID: 33776991.
-
Ciavattone NG, Wu L, O'Neill R, Qiu J, Davila E, Cao X. MyD88 Costimulation in Donor CD8+ T Cells Enhances the Graft-versus-Tumor Effect in Murine Hematopoietic Cell Transplantation. J Immunol. 2021 02 15; 206(4):892-903. PMID: 33408257.
-
Geng D, Ciavattone N, Lasola JJ, Shrestha R, Sanchez A, Guo J, Vlk A, Younis R, Wang L, Brown AJ, Zhang Y, Velasco-Gonzalez C, Tan AC, Davila E. Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. Commun Biol. 2020 06 12; 3(1):306. PMID: 32533049.
-
Guo J, Muse E, Christians AJ, Swanson SJ, Davila E. An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell-Based Cancer Vaccine. Cancer Immunol Res. 2019 09; 7(9):1523-1534. PMID: 31266784.
-
Kaczanowska S, Joseph AM, Guo J, Tsai AK, Lasola JJ, Younger K, Zhang Y, Gonzales CV, Davila E. A Synthetic CD8a:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Res. 2017 12 15; 77(24):7049-7058. PMID: 29055013.
-
Tsai AK, Khan AY, Worgo CE, Wang LL, Liang Y, Davila E. A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. Cancer Immunol Res. 2017 09; 5(9):790-803. PMID: 28775208.
-
Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res. 2015 May 15; 75(10):1959-1971. PMID: 25795705.
-
Li Z, Younger K, Gartenhaus R, Joseph AM, Hu F, Baer MR, Brown P, Davila E. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest. 2015 Mar 02; 125(3):1081-97. PMID: 25642772.
-
Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, McKenna C, Bansal N, Ochoa A, Davila E. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012 Dec 01; 72(23):6209-16. PMID: 23041547.
-
Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012 Dec 01; 18(23):6436-45. PMID: 23032741.
-
Sakoda Y, Park JJ, Zhao Y, Kuramasu A, Geng D, Liu Y, Davila E, Tamada K. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood. 2011 Feb 24; 117(8):2506-14. PMID: 21220749.
-
Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SN, Davila E. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res. 2010 Oct 01; 70(19):7442-54. PMID: 20807806.
-
Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila E. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood. 2010 Nov 04; 116(18):3494-504. PMID: 20696947.
-
Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 2008 Oct; 22(10):3628-37. PMID: 18587008.
-
Davila E, Kang YM, Park YW, Sawai H, He X, Pryshchep S, Goronzy JJ, Weyand CM. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. J Immunol. 2005 Jun 01; 174(11):7292-301. PMID: 15905576.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2005 | 1 | | 2008 | 1 | | 2010 | 2 | | 2011 | 1 | | 2012 | 2 | | 2015 | 2 | | 2017 | 2 | | 2019 | 1 | | 2020 | 1 | | 2021 | 5 | | 2023 | 2 |
To return to the timeline, click here.
|
Davila's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|